Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Venetoclax does not impair activated T-cell proliferation

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Effect of venetoclax on T cells and B cells.

References

  1. Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, et al. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020. [Online ahead of print].

  2. Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, et al. Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019;54:1815–26.

    Article  CAS  Google Scholar 

  3. Bazarbachi AH, Al Hamed R, Malard F, Mohty M, Bazarbachi A. Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant. Ther Adv Hematol. 2019;10:2040620719882666.

    Article  CAS  Google Scholar 

  4. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7:e724–36.

    Article  Google Scholar 

  5. Byrne M, Danielson N, Sengsayadeth S, Rasche A, Culos K, Gatwood K, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am J Hematol. 2020;95:1006–14.

    Article  CAS  Google Scholar 

  6. Wojciechowski S, Tripathi P, Bourdeau T, Acero L, Grimes HL, Katz JD, et al. Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. J Exp Med. 2007;204:1665–75.

    Article  CAS  Google Scholar 

  7. Lu P, Fleischmann R, Curtis C, Ignatenko S, Clarke SH, Desai M, et al. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. Lupus. 2018;27:290–302.

    Article  CAS  Google Scholar 

  8. Khaw SL, Mérino D, Anderson MA, Glaser SP, Bouillet P, Roberts AW, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014;28:1207–15.

    Article  CAS  Google Scholar 

  9. Malard F, Labopin M, Yakoub-Agha I, Chantepie S, Guillaume T, Blaise D, et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. Blood. 2017;130:2186–95.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the clinical teams who provided care for the study patients, and the Tumorotheque of Saint-Antoine Hospital.

Author information

Authors and Affiliations

Authors

Contributions

All authors listed on the manuscript have contributed substantially to this work. LS, BG, MM, and FM designed the study, LS, BG, LR, NS and YY contributed the flow cytometry data, and LS and FM performed the statistical analysis. LS, BG, and FM prepared the manuscript and figures for publication.

Corresponding author

Correspondence to Florent Malard.

Ethics declarations

Conflict of interest

MM reports grants and/or lecture honoraria from Janssen, Sanofi, MaaT Pharma, JAZZ Pharmaceuticals, Celgene, Amgen, BMS, Takeda, Pfizer, and Roche. FM reports lecture honoraria from Therakos/Mallinckrodt, Biocodex, Janssen, Keocyt, Sanofi, JAZZ Pharmaceuticals, and Astellas, all outside the submitted work. The other authors did not disclose any relevant conflict of interest in relation to this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Siblany, L., Gaugler, B., Stocker, N. et al. Venetoclax does not impair activated T-cell proliferation. Bone Marrow Transplant 56, 1740–1742 (2021). https://doi.org/10.1038/s41409-021-01245-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01245-6

Search

Quick links